US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and
Recent breakthroughs in DNA sequencing, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota, an interconnecte
